BRAF and colorectal carcinoma: The BRAF V600E mutation (representing 95% of all CRC-related BRAF mutations) is only encountered in about 8% of metastatic CRC (mCRC) patients (2, 3), however it is associated with poor prognosis and a highly aggressive behavior, including resistance to currently available therapies and predilection for metastasis to distant lymph nodes and the peritoneum (4, 5).